- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
- GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.